Immunome, Inc.

Immunome, Inc.

IMNM·NASDAQ

$19.78

-0.15%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.89B
EPS-2.4300
P/E Ratio-8.14
Earnings Date08/05/2026

imnm

Cash at Beginning of Period

Last Annual Value

143.45M

3-Year CAGR

43%

5-Year CAGR

122%

10-Year CAGR

31%

Immunome, Inc.

Immunome, Inc. Competitors Analysis of Cash at Beginning of Period

IMNM · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
143.45M
91.5%29.2%N/A 
319.83M
68.1%N/AN/A
240.35M
-23.4%7.9%12.2%
25.83M
14.9%N/AN/A
197.90M
25.1%N/AN/A
28.36M
-1.2%-8.3%-8.9%
92.65M
28.4%11.4%N/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
102.54M
-25.0%4.2%N/A
89.42M
34.9%-0.6%11.8%
Immunome, Inc.

Immunome, Inc. Fair Value Envelope

IMNM · NASDAQ

Our analysis suggests that IMNM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $19.78, this represents a potential HIDDEN relative to our calculated worth for Immunome, Inc..

Intrinsic Value
Current Price: $19.78